Acting on its authorization to acquire up to 10% of its shares the H. Lundbeck Supervisory Board has resolved to initiate a share buyback program. Under the program H. Lundbeck will buy own shares for an amount of up to DKK 6 billion until end of 2007, cf. stock exchange announcement number 166 on 17th August 2005. During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on the Copenhagen Stock Exchange, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003. At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program. The following transactions have been made under the program: No. of shares Average Transaction value purchase price (DKK) (DKK) Accumulated, last 19,818,204 135.4678 2,684,728,314 announcement 22 May 2007 158,479 133.0742 21,089,459 1 June 2007 170,089 127.6542 21,712,579 4 June 2007 20,595 126.7202 2,609,803 6 June 2007 133,953 127.1724 17,035,126 7 June 2007 204,073 126.2404 25,762,250 8 June 2007 122,900 125.1956 15,386,540 11 June 2007 7,276 128.2931 933,460 Accumulated under the 20,635,569 135.1675 2,789,257,535 program Following the above buyback it is hereby announced that Lundbeck owns a total of 7,346,426 own shares at a nominal value of DKK 5, equal to 3.45% of the total number of 212,738,273 shares. The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Investor Relations Manager, Media Relations Manager North America +45 36 43 26 38 +1 201 350 0187 ________________________ Stock Exchange Release No 277 - 11 June 2007 About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com